These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 30730636)

  • 1. Edoxaban (Lixiana°).
    Prescrire Int; 2017 Jan; 26(178):13-14. PubMed ID: 30730636
    [No Abstract]   [Full Text] [Related]  

  • 2. The new oral anticoagulants: Reasonable alternatives to warfarin.
    Roca B; Roca M
    Cleve Clin J Med; 2015 Dec; 82(12):847-54. PubMed ID: 26651894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Edoxaban: a review in nonvalvular atrial fibrillation.
    McCormack PL
    Am J Cardiovasc Drugs; 2015 Oct; 15(5):351-61. PubMed ID: 26369340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48.
    Plitt A; Ezekowitz MD; De Caterina R; Nordio F; Peterson N; Giugliano RP;
    Clin Cardiol; 2016 Jun; 39(6):345-6. PubMed ID: 27028520
    [No Abstract]   [Full Text] [Related]  

  • 5. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial.
    Boriani G; Ruff CT; Kuder JF; Shi M; Lanz HJ; Rutman H; Mercuri MF; Antman EM; Braunwald E; Giugliano RP
    Eur Heart J; 2019 May; 40(19):1541-1550. PubMed ID: 30624719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Edoxaban or standard therapy with warfarin for stroke prevention in patients with atrial fibrillation?
    Plitt A; Giugliano RP
    Future Cardiol; 2014 Mar; 10(2):153-5. PubMed ID: 24762238
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
    Kato ET; Giugliano RP; Ruff CT; Koretsune Y; Yamashita T; Kiss RG; Nordio F; Murphy SA; Kimura T; Jin J; Lanz H; Mercuri M; Braunwald E; Antman EM
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial.
    Fanola CL; Ruff CT; Murphy SA; Jin J; Duggal A; Babilonia NA; Sritara P; Mercuri MF; Kamphuisen PW; Antman EM; Braunwald E; Giugliano RP
    J Am Heart Assoc; 2018 Aug; 7(16):e008987. PubMed ID: 30369307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
    Magnani G; Giugliano RP; Ruff CT; Murphy SA; Nordio F; Metra M; Moccetti T; Mitrovic V; Shi M; Mercuri M; Antman EM; Braunwald E
    Eur J Heart Fail; 2016 Sep; 18(9):1153-61. PubMed ID: 27349698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [IQWiG confirms significant additional applications for edoxaban ].
    MMW Fortschr Med; 2015 Dec; 157(21-22):86. PubMed ID: 26960886
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
    Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
    Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease.
    Qamar A; Antman EM; Ruff CT; Nordio F; Murphy SA; Grip LT; Greenberger NJ; Yin OQP; Choi Y; Lanz HJ; Mercuri MF; Braunwald E; Giugliano RP
    J Am Coll Cardiol; 2019 Jul; 74(2):179-189. PubMed ID: 31296289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
    Mega JL; Walker JR; Ruff CT; Vandell AG; Nordio F; Deenadayalu N; Murphy SA; Lee J; Mercuri MF; Giugliano RP; Antman EM; Braunwald E; Sabatine MS
    Lancet; 2015 Jun; 385(9984):2280-7. PubMed ID: 25769357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Edoxaban (Savaysa) for the Prevention of Thromboembolic Events.
    Oung AB
    Am Fam Physician; 2018 Apr; 97(8):529-530. PubMed ID: 29671492
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial.
    Chao TF; Chen SA; Ruff CT; Hamershock RA; Mercuri MF; Antman EM; Braunwald E; Giugliano RP
    Eur Heart J; 2019 May; 40(19):1518-1527. PubMed ID: 30590425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation.
    Yu HT; Yang PS; Kim TH; Jang E; Kim D; Uhm JS; Kim JY; Pak HN; Lee MH; Lip GYH; Joung B
    Stroke; 2018 Oct; 49(10):2421-2429. PubMed ID: 30355093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial.
    Corbalán R; Nicolau JC; López-Sendon J; Garcia-Castillo A; Botero R; Sotomora G; Horna M; Ruff CT; Hamershock RA; Grip LT; Antman EM; Braunwald E; Giugliano RP
    J Am Coll Cardiol; 2018 Sep; 72(13):1466-1475. PubMed ID: 30236308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Edoxaban for the prevention of stroke in patients with atrial fibrillation.
    Cervantes CE; Merino JL; Barrios V
    Expert Rev Cardiovasc Ther; 2019 Apr; 17(4):319-330. PubMed ID: 30897988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
    Lip GY; Merino J; Ezekowitz M; Ellenbogen K; Zamoryakhin D; Lanz H; Jin J; Al-Saadi N; Mercuri M; Goette A
    Am Heart J; 2015 May; 169(5):597-604.e5. PubMed ID: 25965706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis.
    Steffel J; Giugliano RP; Braunwald E; Murphy SA; Mercuri M; Choi Y; Aylward P; White H; Zamorano JL; Antman EM; Ruff CT
    J Am Coll Cardiol; 2016 Sep; 68(11):1169-1178. PubMed ID: 27609678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.